PAREXEL's Bio/pharmaceutical R & D Statistical SourcebookPAREXEL International Corporation, 2008 - Drugs |
From inside the book
89 pages matching pharmaceutical companies in this book
Page v
Where's the rest of this book?
Results 1-3 of 89
Contents
Pharmaceuticals | 1 |
RD Spending at Top 50 Pharmaceutical Companies in 2007 | 7 |
RD Spending by Geographic Area Ethical Pharmaceuticals PhRMA Member Companies 2006 | 13 |
Copyright | |
32 other sections not shown
Other editions - View all
Common terms and phrases
active Amgen analysis Anti-Infective applications approval phase approved drug Assessment AstraZeneca attrition average Biogen Idec biological products biopharmaceutical biotech biotechnology Bristol-Myers Squibb cancer Cardiovascular CBER CDER CenterWatch clinical development clinical investigators clinical phase clinical research clinical studies clinical trials compounds cycle database diabetes DiMasi disease Division Drug Development drugs approved EMEA estimates Fast Track FDA approval FDA review FDA's firms focus Genentech GlaxoSmithKline global Goldman Sachs growth increase innovation late-stage launch Lilly mean approval mean clinical median Merck million months NCES NME approvals Novartis oncology orphan drugs patient recruitment percent period Pfizer Pharma Pharmaprojects Phase Phase preclinical priority Product Approvals programs projects protocol R&D pipeline R&D productivity R&D spending regulatory Roche Sanofi-Aventis Schering-Plough Source sponsors strategy Study of Drug submission Success Rates Costs/Complexity targets therapeutic areas Therapeutic Category therapy trial enrollments Tufts Center Tufts CSDD vaccines Wyeth